Rashmi Kanagal-Shamanna

Mar 18, 2024 | nature.com | Feiyang Ma |Kelly S. Chien |Sanam Loghavi |Guillermo Montalban-Bravo |Vera Adema |Rashmi Kanagal-Shamanna | +2 more

AbstractThe molecular mechanisms of venetoclax-based therapy failure in patients with acute myeloid leukemia were recently clarified, but the mechanisms by which patients with myelodysplastic syndromes (MDS) acquire secondary resistance to venetoclax after an initial response remain to be elucidated.

Feb 7, 2024 | nature.com | Feiyang Ma |Natalia Baran |Jintan Liu |Ken Furudate |Paola Storti |Irene Ganan-Gomez | +10 more

AbstractDNA damage resistance is a major barrier to effective DNA-damaging therapy in multiple myeloma (MM). To discover mechanisms through which MM cells overcome DNA damage, we investigate how MM cells become resistant to antisense oligonucleotide (ASO) therapy targeting Interleukin enhancer binding factor 2 (ILF2), a DNA damage regulator that is overexpressed in 70% of MM patients whose disease has progressed after standard therapies have failed.

Oct 13, 2023 | annualreviews.org | Rashmi Kanagal-Shamanna |David Beck |Katherine R. Calvo

Annual Review of Pathology: Mechanisms of Disease Vol. 19:- (Volume publication date January 2024) Review in Advance first posted online on October 13, 2023. (Changes may still occur before final publication.) https://doi.org/10.1146/annurev-pathmechdis-051222-122724 *These authors contributed equally to this article

Aug 22, 2023 | onlinelibrary.wiley.com | Guillermo Montalban-Bravo |Rashmi Kanagal-Shamanna |Ziyi Li |Danielle Hammond

CONFLICT OF INTEREST STATEMENT K.S. declares honoraria from Otsuka Pharma, and consultancy fee from Pfizer Japan. M.K. declares consulting and honoraria from AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, Amgen, Forty-Seven, and Kisoji; research funding and/or clinical trial support from AbbVie, Genentech, F. Hoffman La-Roche, Eli Lilly, Cellectis, Calithera, Ablynx, Stemline Therapeutics, Agios, Ascentage and Astra Zeneca; and stock options/royalties from Reata Pharmaceutical.